Barry R. Walker
Fundador en American Society of Hypertension .
Perfil
Barry R.
Walker is the founder of American Society of Hypertension.
He worked as a Senior Vice President of Research & Development at Wyeth-Ayerst Research and as an Adjunct Associate Professor of Medicine at the University of Pennsylvania.
He also served as an Independent Non-Executive Director at Botanix Pharmaceuticals Ltd.
and as SVP-Regulatory & Clinical Development at Ceptaris Therapeutics, Inc. He holds a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Yale University.
Cargos activos de Barry R. Walker
Empresas | Cargo | Inicio |
---|---|---|
American Society of Hypertension | Fundador | 16/03/2011 |
Antiguos cargos conocidos de Barry R. Walker.
Empresas | Cargo | Fin |
---|---|---|
University of Pennsylvania | Corporate Officer/Principal | - |
BOTANIX PHARMACEUTICALS LIMITED | Director/Miembro de la Junta | 19/08/2011 |
Wyeth-Ayerst Research | Director Técnico/Científico/I+D | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Consejero General | 22/03/2011 |
Formación de Barry R. Walker.
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Yale University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BOTANIX PHARMACEUTICALS LIMITED | Health Technology |
Empresas privadas | 3 |
---|---|
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Wyeth-Ayerst Research | |
American Society of Hypertension |
- Bolsa de valores
- Insiders
- Barry R. Walker